Company Introduction
SURI Biotech is a biotech platform developing health-promoting bacterial strains with unique mechanisms of action for the alleviation of bloating and intestinal discomfort. BactoKind, our first application, is a food supplement for the alleviation of infant colic. BactoKind strains compete with hydrogengas- producing bacteria, preventing gas formation and consequently reducing bloating, pain and crying in colic babies.
BactoKind, is the first solution for infant colic with a scientifically proven mechanism of action.
Product Portfolio & Key Technologies
Key technology: Our unique value proposition relays on our mechanistic understanding of bloating gained after performing research for more than 12 years on microbial gut colonization and on our proprietary strains rationally selected for preventing lactate and hydrogen production by intestinal microorganisms.
BactoKind: BactoKind, our first application, is a food supplement for the alleviation of infant colic.
Product pipeline: SURI Biotech, plans to develop at least 2 further applications based on the same mechanism of action: Lactose intolerance and Irritable Bowel Syndrome (IBS)
M&A, Partnerships or Customers
To scale up the production of BactoKind, we look for sub-contracting fermentation services (CMOs).
In view of a market launch in 2024, we require to build commercial relationships with brand owners and food ingredients distributors.
Link to Precision Nutrition
The microbiome represents a new area of science with potential to improve human health. At SURI BioTech we untangle the potential of the gut microbiome using rationally selected bacterial strains with clear targets and high efficacy for the alleviation of bloating and gastrointestinal discomfort.
